Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)

Sponsor
Centre Hospitalier William Morey - Chalon sur Saône (Other)
Overall Status
Recruiting
CT.gov ID
NCT05608902
Collaborator
(none)
30
1
6.8
4.4

Study Details

Study Description

Brief Summary

Basal cell carcinoma (BCC) are the most frequent skin cancers. Their incidence is constantly increasing. BCC diagnosis is first clinically suspected and then confirmed following histological examination of either a skin biopsy or the excisional specimen. Surgery is the first-line treatment and some procedures (notably Mohs surgery) require extemporaneous histological analysis of the edges to ensure a complete excision. Such on-site histopathological examination can be time consuming and associated with decreased sensitivity. Skin imaging techniques have already been tested to overcome these limitations and seem promising. Although some of them - such as confocal microscopy - are already even used in vivo, there is to date no report of the use of full-field optical coherence tomography for the diagnosis of BCC.

The DOCTOBA study intends to describe direct histopathological examination of fresh skin biopsy or excisional specimen with dynamic full-field optical coherence tomography.

Condition or Disease Intervention/Treatment Phase
  • Other: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study
Actual Study Start Date :
Sep 6, 2022
Actual Primary Completion Date :
Jan 26, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
DOCTOBA cohort

Patients > 18 years of age with suspected basal cell carcinoma requiring biopsy or skin resection in the dermatology department

Other: Dynamic full-field optical coherence tomography analysis of skin biopsy or resection
Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis

Outcome Measures

Primary Outcome Measures

  1. Histopathological analysis of basal cell carcinoma with dynamic full-field optical coherence tomography [Outcome measure is assessed 15 days following skin biopsy or resection]

    Provide a better understanding of the ability of dynamic full-field optical coherence tomography to identify and characterize the usual basal cell carcinoma, comprising basaloid cells with a thin pale cytoplasm surrounding round or oval nuclei with a rough granulated chromatin pattern, palisade arrangement, artificially created slits, rather chaotic internal arrangement, mitoses and necrosis ; but also to identify the different sub-types of basal cell carcinoma (nodular, superficial, infiltrating, scleroderma).

Secondary Outcome Measures

  1. Histopathological analysis of healthy skin with dynamic full-field optical coherence tomography [Outcome measure is assessed 15 days following skin biopsy or resection]

    Provide a better understanding of the ability of dynamic full-field optical coherence tomography to identify the normal structures of the skin (meaning not affected by carcinoma), i.e. the different layers of the skin (epidermis, dermis and subcutaneous tissue) and the skin appendages (hair follicles and glands), also to recognize the different cells and components (keratinocytes, melanocytes, Langerhans cells, Merkel celles and collagen) and underlayers (stratum corneum, stratum granulosum, stratum spinosum, stratum basale, epidermal cretes, dermo-hypodermic junction, papillary dermis and reticularis dermis).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patient > 18 years of age who received skin biopsy or excision of basal cell carcinoma suspected lesion between start study date and primary completion date
Exclusion Criteria:
  • inability to perform dynamic full-field optical coherence tomography observation at the moment of skin biopsy

  • diagnosis of basal cell carcinoma disproved

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier William Morey - Chalon sur Saône Chalon sur Saône Saône-et-Loire France 71100

Sponsors and Collaborators

  • Centre Hospitalier William Morey - Chalon sur Saône

Investigators

  • Principal Investigator: Thomas Maldiney, Centre Hospitalier William Morey - Chalon sur Saône

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Thomas Maldiney, Doctor, Centre Hospitalier William Morey - Chalon sur Saône
ClinicalTrials.gov Identifier:
NCT05608902
Other Study ID Numbers:
  • DermatOCT1
First Posted:
Nov 8, 2022
Last Update Posted:
Jan 27, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2023